



## **Urine Drug Analysis Test No. 15-5671 Summary Report**

---

This test was sent to 72 participants. Each sample set contained three cases with individual scenarios, each containing one specimen bottle of human urine. Participants were requested to examine these items and report their findings. Data were returned from 52 participants (72.2% response rate) and are compiled into the following tables:

	<u>Page</u>
<a href="#"><u>Manufacturer's Information</u></a>	<a href="#"><u>2</u></a>
<a href="#"><u>Summary Comments</u></a>	<a href="#"><u>3</u></a>
<a href="#"><u>Table 1: Item 1 Results</u></a>	<a href="#"><u>4</u></a>
<a href="#"><u>Table 2: Item 2 Results</u></a>	<a href="#"><u>25</u></a>
<a href="#"><u>Table 3: Item 3 Results</u></a>	<a href="#"><u>41</u></a>
<a href="#"><u>Table 4: Additional Test Comments</u></a>	<a href="#"><u>56</u></a>
<a href="#"><u>Appendix: Data Sheet</u></a>	<a href="#"><u>57</u></a>

This report contains the data received from the participants in this test. Since these participants are located in many countries around the world, and it is their option how the samples are to be used (e.g., training exercise, known or blind proficiency testing, research and development of new techniques, etc.), the results compiled in the Summary Report are not intended to be an overview of the quality of work performed in the profession and cannot be interpreted as such. The Summary Comments are included for the benefit of participants to assist with maintaining or enhancing the quality of their results. These comments are not intended to reflect the general state of the art within the profession.

Participant results are reported using a randomly assigned "WebCode". This code maintains participant's anonymity, provides linking of the various report sections, and will change with every report.

## Manufacturer's Information

The sample sets contained urine samples from three cases, each with an individual case scenario. Each case sample consisted of one specimen bottle containing 50mL of human urine. Participants were requested to analyze the urine samples and report the presence of any drugs/metabolites, any quantitative data obtained (including uncertainty), methods used, and any additional comments.

### SAMPLE PREPARATION-

The urine used in this test was from the same lot, which tested negative for a variety of common drugs and controlled substances prior to being obtained from a commercial supplier.

A stock solution of each drug was used to spike each item. These solutions were obtained in sealed ampoules and were not opened until needed for production. Items were prepared at separate times using the following procedure, and different glassware was used for each item.

ITEMS 1, 2, and 3 (PREPARATION): Sample preparation consisted of adding a predetermined amount of drug stock solution to a beaker containing human urine, where the equivalent of 2% w/v sodium fluoride was added and then stirred with a magnetic stirrer for at least 20 minutes. 50mL of the mixture was then transferred into each of the pre-labeled specimen bottles. All bottles were stored in a refrigerator immediately after production until the sample sets were prepared.

SAMPLE SET ASSEMBLY: Each sample set contained Items 1, 2, and 3 and was placed into a Department of Transportation regulated shipping container. Each sample pack was labeled and returned to the refrigerator until shipment.

### VERIFICATION-

Two out of three of the laboratories that conducted predistribution analysis of the samples reported the expected drugs and/or a minimum of one expected metabolite per drug. One laboratory did not report 11-nor-9-carboxy- $\Delta^9$ -THC for Item 1. After an investigation, CTS determined that the samples were acceptable and released the test.

<u>Item 1 Drug (Concentration)</u>	<u>Item 2 Drug (Concentration)</u>	<u>Item 3 Drug (Concentration)</u>
Alprazolam (300ng/mL)	Benzoyllecgonine (2000ng/mL)*	Fentanyl (75ng/mL)
Alpha-hydroxyalprazolam (400ng/mL)	Ecgonine methyl ester (400ng/mL)	Norfentanyl (260ng/mL)
11-nor-9-carboxy- $\Delta^9$ -THC (100ng/mL)		

Please note that the Preparation Value is the value used for calculations during the test preparation phase and may not necessarily represent the final concentration of the samples. It is advised to wait for the Grand Mean statistics available in the Summary and Individual Reports before evaluating performance.

**\*Updated February 26, 2016** - CTS has been notified by the manufacturer that the benzoyllecgonine standard used to produce Item 2 contained a cocaine impurity at 0.27%, resulting in an expected cocaine concentration of approximately 5 ng/mL.

## **Summary Comments**

This test was designed to allow participants to assess their proficiency in the examination for the presence and concentration of drugs and/or metabolites in urine. Each participant was supplied with one specimen bottle containing 50mL of human urine spiked with differing drugs and/or metabolites for each of three case scenarios. Participants were asked to report the presence of any drugs/metabolites, any quantitative data obtained (including uncertainty), methods used, and any additional comments. (Refer to the Manufacturer's Information for preparation details.)

Of the 50 participants who reported screening results for Item 1, 47 (94.0%) reported the presence of benzodiazepines and 42 (84.0%) reported the presence of cannabinoids. Five participants (10.0%) reported the presence of alprazolam and/or alpha-hydroxyalprazolam and 4 participants reported the presence of 11-nor-9-carboxy- $\Delta$ 9-THC. One participant reported the presence of an analyte not consistent with the consensus. Of the 50 participants who reported confirmatory results for Item 1, 42 (84.0%) reported the presence of alprazolam and 25 (50.0%) also reported alpha-hydroxyalprazolam. Thirty-five (70.0%) participants reported the presence of 11-nor-9-carboxy- $\Delta$ 9-THC. Twelve participants (24.0%) reported analytes in a form not consistent with the consensus and one reported no drugs/metabolites detected.

Of the 49 participants who reported screening results for Item 2, 42 (85.7%) reported the presence of cocaine and 10 (20.4%) reported the presence of benzoylecgonine and/or ecgonine methyl ester. Of the 48 participants who reported confirmatory results for Item 2, 43 (89.6%) reported the presence of benzoylecgonine and/or ecgonine methyl ester. Nine participants (18.8%) reported analytes not consistent with the consensus (eight of these were cocaine; see below) and two reported no drugs/metabolites detected.

Several participants reported the presence of cocaine in the confirmatory results for Item 2. It was investigated whether the certified reference materials for benzoylecgonine and/or ecgonine methyl ester that were used to produce this item could contain a contaminant. It was determined that any contaminants would be in quantities significantly lower than that reported. Since the Item 2 samples were only prepared with the metabolites and not the parent drug cocaine, and a consensus was not reached on the presence of cocaine in the confirmatory results, those results have been highlighted.

Of the 48 participants who reported screening results for Item 3, 18 (37.5%) reported the presence of fentanyl and/or norfentanyl. Two participants reported the presence of opiates and/or narcotics and 2 reported results not consistent with the consensus. Twenty-nine (60.4%) reported no drugs/metabolites detected. Of the 45 participants who reported confirmatory results for Item 3, 36 (80.0%) reported the presence of Fentanyl and 14 (31.1%) also reported the presence of norfentanyl. Eight (17.8%) participants reported no drugs/metabolites detected and one reported analytes not consistent with the consensus.

If a participant indicated that the confirmatory quantitative result was a single determination, the conclusive quantitative result was included in the raw data table. Due to the small sample number of participants who reported quantitative information, no grand mean statistics were calculated or determinations regarding "extreme" data made.

# Screening Results - Item 1

TABLE 1A Item 1

**Item 1 Scenario:**

Case 1: A 25-year-old female was arrested for possession of Diazepam without a prescription last year and is subject to drug testing as part of her parole. After her parole officer observed her exhibiting poor balance, slurred speech, and trouble concentrating, he ordered that she submit to a drug test. Her urine sample has been submitted for analysis.

**Item Contents and Preparation Concentration:** Alprazolam (300ng/mL)  
 Alpha-hydroxyalprazolam (400ng/mL)  
 11-nor-9-carboxy- $\Delta$ 9-THC (100ng/mL)

Webcode	Screening Results
2UUFXZ	THC, Benzodiazepines
3C7PB7	benzodiazepines, Cannabinoid
424NC8	Benzodiazepines and Cannabinoids
4GZUQW	Benzodiazepines, Cannabis
4X4DF8	CANNABINOIDS & BENZODIAZEPINES Panels
69GZ4Y	THC -M and BENZODIAZEPINES
77QDMV	Class: Benzodiazepines, Class: Cannabinoids
7AUYKT	Cannabis, Benzodiazepines
7T2DVT	Benzodiazepines, Cannabinoids
83JHFX	THC 50, Benzodiazepine 200
8K7XJU	Cannabinoids, Benzodiazepines
AUM24Y	Benzodiazepines, Marijuana metabolite
BCGGGU	CANNABINOID AND BENZODIAZEPINE
BP7F9W	Benzodiazepines, THC

TABLE 1A Item 1

<b>Webcode</b>	<b>Screening Results</b>
CGQUYT	THC-DELTA 9, BEZODIACEPINES[sic]
CKQ6VT	BENZODIAZEPINES, CANNABINOIDS ( 11-NOR-9-CARBOXY-THC)
CMT7VP	Benzodiazepines, Cannabinoids
EQ8KCV	Benzodiazepines, Cannabinoids
ETT6JK	THC-COOH, ALPRAZOLAM
F63YCP	Cannabinoids and Benzodiazepines
FGY66M	1 - Benzodiazapines[sic], 2 - THC 50
FQK9CM	Alprazolam
FX3H2J	Benzodiazepines
G84PTN	CANNABINOIDS, BENZODIAZEPINE
GGUAYL	Benzodiazepines, cannabinoids.
H789GR	THC, Benzodiazepines
H797RM	Cannabinoids, Benzodiazapines[sic]
JRLDFL	Cannabinoids, Benzodiazepines
K9TWRH	1) Benzodiazepines, 2) Cannabinoids
KJQX4L	11-carboxy-THC, Benzodiazepines/Alprazolam
KTGAPF	benzodiazepines, cannabinoids, alprazolam, hydroxyalprazolam

TABLE 1A Item 1

Webcode	Screening Results
LX2XDH	alpha-hydroxyalprazolam, alprazolam
MD9C9K	THC Metabolite, Benzodiazepines[sic]
P4V2VB	Benzodiazepines, THC/Marijuana
PUAXNC	Benzodiazepines, THC-COOH
QHWXRH	screened positive for benzodiazepine and cannabinoid class compounds
QHXY3E	Benzodiazepines and cannabinoids
QJTD4F	CANNABINOIDS, BENZODIAZEPINE
R92EQF	Benzodiazepines, Cannabinoids
RAWXRG	Benzodiazepines, Cannabinoids
RREYMJ	Benzodiazepines and Cannabinoids
TUY6L7	Cannabinoids, Benzodiazepines
UKTVE8	Benzodiazepines Class and Cannabinoids Class
WKHTVC	Benzodiazepines, Cannabinoids
WVJ726	Benzodiazepines and Cannabinoids
X7V6Z6	Benzodiazepine, Cannabinoids
XHCPK2	Benzodiazepines (Diazepam)
Y3QWAZ	Benzodiazepines

TABLE 1A Item 1

<b>Webcode</b>	<b>Screening Results</b>
YMYY86	Cannabinoids, benzodiazepines
YUZB42	Benzodiazepines, Cannabinoids

<b>Response Summary for Item 1</b>	<b>Participants: 50</b>
Benzodiazepines:	47
Cannabinoids:	42
Alprazolam and/or Alpha-hydroxyalprazolam:	5
11-nor-9-carboxy- $\Delta$ 9-THC:	4
Other:	1
<b>Totals may add up to more than the total number of participants because some participants reported multiple classes/drug names.</b>	

# Confirmatory Results - Item 1

*What drugs/metabolites were detected in Item 1?*

TABLE 1B Item 1

**Item 1 Scenario:**

Case 1: A 25-year-old female was arrested for possession of Diazepam without a prescription last year and is subject to drug testing as part of her parole. After her parole officer observed her exhibiting poor balance, slurred speech, and trouble concentrating, he ordered that she submit to a drug test. Her urine sample has been submitted for analysis.

**Item Contents and Preparation Concentration:** Alprazolam (300ng/mL)  
 Alpha-hydroxyalprazolam (400ng/mL)  
 11-nor-9-carboxy- $\Delta$ 9-THC (100ng/mL)

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
2UUFXZ	Alprazolam	✓			
	THCC	✓			
3C7PB7	Alprazolam	✓			
	alpha-hydroxyalprazolam	✓			
	delta-9-carboxy-THC	✓			
424NC8	alprazolam	✓			
	carboxy-THC	✓			
4GZUQW	Alprazolam	✓			
	alpha hydroxyalprazolam	✓			
	Carboxy-THC	✓			
69GZ4Y	URINE				
6ZQEYZ	11-NOR- DELTA 9 TCH-COOH[sic]	✓			
77QDMV	Alprazolam	✓			
	11-nor-9-Carboxy- Tetrahydrocannabinol (Marijuana Metabolite)	✓			
7AUYKT	Alprazolam		474		$\mu$ g/L
	Cannabis		90		$\mu$ g/L



TABLE 1B Item 1

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
7T2DVT	Alprazolam	✓			
	Alpha-OH-alprazolam	✓			
	11-Nor-9-Carboxy-delta-9-tetrahydrocannabinol	✓			
7ZKJRZ	ALPRAZOLAM	✓			
	1-COOH-TETRAHIDROCANNABINOL[sic]	✓			
83JHFX	Alprazolam	✓			
	THC-COOH	✓			
8K7XJU	Alprazolam	✓			
	Hydroxyalprazolam	✓			
	THC metabolite	✓			
AUM24Y	Alprazolam	✓			
	Alpha-Hydroxyalprazolam		376	42	ng/mL
	11-nor-9-carboxy-delta-9-tetrahydrocannabinol		82	23	ng/mL
BCGGGU	ALPRAZOLAM	✓			
	HIDROXIALPRAZOLAM[sic]	✓			
	ACID 11-NOR DELTA 9-THC-CARBOXILIC[sic]	✓			
BP7F9W	Alprazolam	✓			
	alpha-Hydroxyalprazolam	✓			
	Delta-9-THC-COOH	✓			
CGQUYT	ALPRAZOLAM	✓			
	11-HIDROXI-DELTA9-TETRAHIDROCANNABINOL[sic]	✓			
CKQ6VT	DELTA 9-THC-COOH	✓			
	DESMETHYLDIAZEPAM	✓			

TABLE 1B Item 1

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
CMT7VP	Alprazolam	✓			
	Alpha-hydroxy-alprazolam	✓			
	Tetra-hydro-cannabinol-carboxylic acid (THC-COOH)	✓			
EQ8KCV	Alprazolam	✓			
	Alpha-Hydroxyalprazolam	✓			
	11 nor delta 9 THC 9 carboxylic acid	✓			
ETT6JK	ALPRAZOLAM	✓			
	THC-COOH	✓			
F63YCP	Alprazolam	✓			
	Hydroxyalprazolam	✓			
	Delta-9-tetrahydrocannabinol-9-carboxylic acid		86		ng/mL
FGY66M	Alprazolam	✓			
	Tetrahydrocannabinol	✓			
FQK9CM	urine Sample	✓			
FX3H2J	Alprazolam		308.31	±61.7	ng/mL
	Alpha-hydroxy alprazolam		427.16	±85.4	ng/mL
G84PTN	ALPRAZOLAM	✓			
	ACID-11-NOR-DELTA-9-THC	✓			
GGUAYL	Alprazolam	✓			
	THC-COOH	✓			
H789GR	alprazolam	✓			
	11-nor-delta-9-carboxy THC	✓			

TABLE 1B Item 1

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
H797RM	Alprazolam	✓			
	Hydroxyalprazolam	✓			
	THC Metabolite	✓			
JRLDFL	Alprazolam	✓			
	Hydroxyalprazolam	✓			
	THC Metabolite	✓			
K9TWRH	alprazolam	✓			
	Hydroxy alprazolam	✓			
	tetrahydrocannabinol[sic] metabolite	✓			
KJQX4L	Alprazolam	✓			
	alpha-hydroxy[sic] alprazolam	✓			
	11-carboxy-THC		86	16	ng/mL
KTGAPF	alprazolam		230	15%	ng/mL
	alpha-hydroxyalprazolam		360	20%	ng/mL
	carboxytetrahydrocannabinol		92	20%	ng/mL
LX2XDH	alprazolam	✓			
MD9C9K	Alprazolam	✓			
	Hydroxyalprazolam	✓			
	THC Metabolite	✓			
P4V2VB	No drugs/metabolites detected.				
PUAXNC	Alprazolam	✓			
	THC-COOH	✓			

TABLE 1B Item 1

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
QHWXRH	Alprazolam	✓			
	alpha-hydroxyalprazolam	✓			
	carboxy-THC	✓			
QHXV3E	alprazolam	✓			
	Carboxy-THC	✓			
QJTD4F	11-COOH-TETRAHYDROCANABINOL[sic]	✓			
R92EQF	Alprazolam	✓			
	alpha-Hydroxyalprazolam	✓			
	9-carboxy-THC	✓			
RAWXRG	Alprazolam	✓			
	Hydroxyalprazolam	✓			
	Carboxytetrahydrocannabinol	✓			
RREYMJ	Alprazolam	✓			
	THC-COOH	✓			
TUY6L7	Alprazolam	✓	Positive		
	THC-COOH	✓	Positive		
UKTVE8	11-Nor-9-Carboxy-delta 9-THC	✓			
WKHTVC	Alprazolam	✓			
	Alpha-hydroxyalprazolam	✓			
	Carboxy-THC	✓			
WVJ726	Alprazolam	✓			
	Alpha-hydroxyalprazolam	✓			
	11-Nor-9-carboxy-delta-9-tetrahydrocannabinol	✓			

TABLE 1B Item 1

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
X7V6Z6	THC-COOH		81		ng/mL
Y3QWAZ	Alprazolam	✓			
	Alpha-hydroxyalprazolam	✓			
YMY86	Alprazolam		304		ng/mL
	$\alpha$ -hydroxyalprazolam		348		ng/mL
	Carboxy THC		103		ng/mL
YUZB42	Alprazolam	✓			
	Hydroxyalprazolam	✓			
	THC-COOH	✓			

Response Summary for Item 1		Participants: 50
Alprazolam:	42	
Alpha-hydroxyalprazolam:	25	
11-nor-9-carboxy- $\Delta$ 9-THC:	35	
No drugs/metabolites detected:	1	
Other:	12	
<p>Totals may add up to more than the total number of participants because some participants reported multiple drugs/metabolites.</p>		

## **Raw Data - Item 1**

*List of raw data determinations in ng/mL.*

TABLE 1C Item 1  
**Item 1 Raw Data - Alprazolam**  
**Preparation concentration: 300ng/mL**

<b>Webcode</b>	<b>Raw Data (ng/mL)</b>				<b>Participant Mean</b>
7AUYKT	474.000				474.000
FX3H2J	299.230	317.390			308.310
KTGAPF	218.000	229.000	246.000	238.000	232.750
YMYY86	303.500				303.500

### **Statistical Analysis for Item 1 - Alprazolam**

Please note statistical analysis has not been provided due to the low number of raw data responses.

TABLE 1C Item 1  
Item 1 Raw Data - Alpha-hydroxyalprazolam  
Preparation concentration: 400ng/mL

Webcode	Raw Data (ng/mL)		Participant Mean
AUM24Y	376.000		376.000
FX3H2J	419.840	434.480	427.160
KTGAPF	355.000	360.000	357.500
YMY86	348.200		348.200

**Statistical Analysis for Item 1 - Alpha-hydroxyalprazolam**

Please note statistical analysis has not been provided due to the low number of raw data responses.

TABLE 1C Item 1  
Item 1 Raw Data - 11-nor-9-carboxy- $\Delta$ 9-THC  
Preparation concentration: 100ng/mL

Webcode	Raw Data (ng/mL)		Participant Mean
AUM24Y	82.000		82.000
F63YCP	85.670	86.690	86.180
KJQX4L	86.000		86.000
KTGAPF	91.000	93.000	92.000
X7V6Z6	81.920	81.320	81.620
YMY86	102.600		102.600

**Statistical Analysis for Item 1 - 11-nor-9-carboxy- $\Delta$ 9-THC**

Please note statistical analysis has not been provided due to the low number of raw data responses.



TABLE 1C Item 1  
Item 1 Raw Data - Other

Webcode	Analyte	Raw Data (ng/mL)
7AUYKT	Cannabis	90.000

Statistical Analysis for Item 1 - Other
Please note statistical analysis is not provided for other drug responses.

## Reporting Procedures - Item 1

*If quantitative analysis was performed, the reported concentrations are:*

TABLE 1D Item 1

Webcode	Quantitative Reporting Procedures
69GZ4Y	The mean of duplicate/several determinations.
7AUYKT	A single determination.
AUM24Y	A single determination.
F63YCP	The mean of duplicate/several determinations.
FX3H2J	The mean of duplicate/several determinations.
KJQX4L	A single determination.
KTGAPF	The mean of duplicate/several determinations.
QJTD4F	A single determination.
X7V6Z6	The mean of duplicate/several determinations.
YMY86	A single determination.

Response Summary for Item 1	Participants: 10
A single determination:	5 (50.0%)
The mean of duplicate/several determinations:	5 (50.0%)
Other:	0 (0.0%)

## Method of Analysis - Item 1

TABLE 1E Item 1

Webcode	Method	Screening	Confirmatory	Quantitation
2UUFXZ	Immunoassay GC/MS	✓	✓	
3C7PB7	Immunoassay GC/MS LC/MS/MS	✓	✓ ✓	
424NC8	Immunoassay GC/MS	✓	✓	
4GZUQW	Immunoassay GC/MS LC-TOF-MS	✓ ✓	✓ ✓	
4X4DF8	Immunoassay	✓		
69GZ4Y	Immunoassay GC/MS	✓	✓	✓
6ZQEYZ	GC/MS	✓	✓	
77QDMV	Immunoassay GC/MS	✓	✓	
7AUYKT	Immunoassay GC/MS	✓	✓	✓
7T2DVT	Immunoassay GC/MS	✓	✓	
7ZKJRZ	Immunoassay GC/MS	✓	✓	
83JHFX	Immunoassay GC/MS	✓	✓	
8K7XJU	Immunoassay GC/MS	✓ ✓	✓	
AUM24Y	Immunoassay GC/MS	✓	✓	✓
BCGGGU	Immunoassay GC/MS LC/MS/MS	✓	✓ ✓	
BP7F9W	Immunoassay GC/MS	✓	✓	
CGQUYT	Immunoassay GC/MS	✓	✓	

TABLE 1E Item 1

Webcode	Method	Screening	Confirmatory	Quantitation
CKQ6VT	Immunoassay GC/MS	✓	✓	
CMT7VP	Immunoassay GC/MS LC/MS/MS	✓	✓ ✓	
EQ8KCV	Immunoassay GC/MS	✓	✓	
ETT6JK	Immunoassay GC/MS LC/MS/MS	✓ ✓ ✓	✓ ✓	
F63YCP	Immunoassay GC/MS LC/MS/MS	✓	✓ ✓	✓
FGY66M	Immunoassay GC/MS	✓	✓	
FQK9CM	Immunoassay GC/MS	✓	✓	
FX3H2J	Immunoassay GC/MS	✓	✓	✓
G84PTN	Immunoassay GC/MS	✓	✓	
GGUAYL	Immunoassay GC/MS	✓	✓	
H789GR	Immunoassay GC/MS	✓	✓	
H797RM	Immunoassay GC/MS	✓	✓	
JRLDFL	Immunoassay GC/MS	✓ ✓	✓	
K9TWRH	Immunoassay GC/MS LC-Orbitrap	✓	✓ ✓	
KJQX4L	Immunoassay GC/MS LC/MS	✓ ✓	✓ ✓	✓ ✓
KTGAPF	Immunoassay GC/MS LC/MS/MS LC-QTOF	✓ ✓ ✓	✓ ✓	✓

TABLE 1E Item 1

Webcode	Method	Screening	Confirmatory	Quantitation
LX2XDH	GC/MS		✓	
	LC/MS/MS	✓		
	Rapid Chromatographic Immunoassay	✓		
MD9C9K	Immunoassay	✓		
	GC/MS		✓	
P4V2VB	Immunoassay	✓		
PUAXNC	Immunoassay	✓		
	GC/MS		✓	
QHWXRH	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
QH XV3E	Immunoassay	✓		
	GC/MS		✓	
QJTD4F	Immunoassay	✓		
	GC/MS		✓	
R92EQF	Immunoassay	✓		
	GC/MS		✓	
RAWXRG	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
RREYMJ	Immunoassay	✓		
	GC/MS		✓	
TUY6L7	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	
UKTVE8	Immunoassay	✓		
	GC/MS		✓	
WKHTVC	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
WVJ726	Immunoassay	✓		
	GC/MS		✓	
X7V6Z6	Immunoassay	✓		
	GC/MS		✓	✓
XHCPK2	Immunoassay	✓		
	GC/MS		✓	
Y3QWAZ	Immunoassay	✓		
	LC/MS/MS		✓	

TABLE 1E Item 1

Webcode	Method	Screening	Confirmatory	Quantitation
YMYY86	Immunoassay	✓		
	GC/MS	✓	✓	✓
	GC-NPD	✓		
YUZH42	Immunoassay	✓		
	GC/MS		✓	

Response Summary for Item 1		Participants: 52		
		Screening	Confirmatory	Quantitation
<b>Immunoassay:</b>		50	0	0
<b>GC/MS:</b>		8	48	8
<b>LC/MS:</b>		0	1	1
<b>LC/MS/MS:</b>		2	11	1
<b>Other:</b>		4	3	0

## Additional Comments for Item 1

TABLE 1F Item 1

Webcode	Item 1 - Comments
4X4DF8	We utilized ELISA and an Enzymatic Assay (for EtOH) and use Immunalysis Kits. It is not our practice to report a specific analyte as a (+) or (-). Calibrator Levels: ELISA Panels (ng/ml): Amphetamine 50, Benzodiazepines 50, Benzoylcegonine 50, Flunitrazepam 25, Ketamine 10, Methamphetamine 50, Opiates 25, Oxycodone 10, D9-THC 25, Zolpidem 10. Enzymatic Assay (g/dl): Ethyl Alcohol 0.01.
69GZ4Y	11-nor-9-CarboxyD3 -Deuterated[sic] THC used as an Internal Standard.
77QDMV	Internal Standards used: Phenyltoloxamine, Heptabarbital, 11-Hydroxy-THC.
8K7XJU	Internal Standard used for THC confirmation was Cannabinol
AUM24Y	Internal Standards: Nordiazepam-d5, Oxazepam-d5, Temazepam-d5, Alpha-hydroxyalprazolam-d5. Limits of Detection for Oxazepam, Diazepam, Lorazepam, Clonazepam, 7-Amino-Flunitrazepam, Alprazolam, Alpha-Hydroxyalprazolam = 50 ng/mL. Limits of Detection for Nordiazepam, Temazepam = 100 ng/mL. Internal Standard: 11-nor-9-carboxy-delta-9-tetrahydrocannabinol-d9. Limit of Detection for 11-nor-9-carboxy-delta-9-tetrahydrocannabinol = 5 ng/mL.
EQ8KCV	IS-11 nor delta 9 THC 9 carboxylic acid-d3, IS-Phenyltoloxamine, IS-Oxazepam-d5, Cannabinoid cutoff 50 ng/ml.
FGY66M	*(Ibuprofen - Theobromine - oxybenzone) were found in Item 1 sample. *Codeine - d3 and THC-D3 were used as internal standards.
FQK9CM	The technique used for analyzing the sample is Liquid-Liquid Extraction
FX3H2J	No hydrolysis of urine specimen was performed prior to analysis. "Alprazolam-D5" was used as internal standards. Limit of detection was 25 ng/mL.
G84PTN	SCREENING BY IMMUNOASSAY: CUTT-OF CANNABINOIDS:50ng/ml, COCAINE:300ng/ml, BENZODIACEPINAS:200ng/ml, BARBITURATES: 200 ng/ml, OPIATES: 300 ng/ml, AMPHETAMINES:1000 ng/ml. [sic]
GGUAYL	Internal standards used: SKF-525A and D3-THC-COOH.
H789GR	Caffeine indicated by GC-MS (lab would not confirm w/ 2nd test since not controlled).
KTGAPF	ISD for carboxytetrahydrocannabinol quantitation = D3- carboxytetrahydrocannabinol. ISD for alprazolam quantitation = prazepam. ISD for hydroxyalprazolam quantitation = D5-hydroxyalprazolam.
LX2XDH	Alere iCassette (THC) test device was used to screen for THC, referred to in 1-4[Table 1E Item 1 - Method of Analysis] as rapid chromatographic immunoassay.
P4V2VB	Cutoff for benzodiazepines is 300 ng/mL. Cutoff for marijuana is 50 ng/mL.
PUAXNC	Acid Internal Reference Material - Heptabarbital. Base Internal Reference Material - Phenyltoloxamine.
RAWXRG	d5-OH-Alprazolam and d5-Alprazolam used as internal standards for benzodiazepine confirmation; Positive controls at 0.1 and 0.5 mg/L used for QC (LC-MS/MS). d9-Carboxytetrahydrocannabinol used as internal standard for cannabinoid confirmation by GC-MS; positive controls at 0.01 and 0.10 mg/L used for QC.
RREYMJ	SKF-525A and D3-THC-COOH were used as internal standards. Caffeine was also confirmed in the urine sample but was not reported as it was present in all three samples.
UKTVE8	For Item 1, Benzodiazepines class was only screened, no confirmatory test was completed.

TABLE 1F Item 1

Webcode	Item 1 - Comments
X7V6Z6	Benzo- confirmation method detects- diazepam, desmethyldiazepam, temazepam, oxazepam, lorazepam, midazolam and respective internal standards. limit of detection 10ng/mL. Cannabis- confirmation method detects- THC-COOH, internal standard THC- COOH D3. limit of detection 5ng/mL.
XHCPK2	Analysed using randox evidence.
YUZB42	Immunoassay was used for Screening. GC/MS was used for Confirmation.



## Screening Results - Item 2

TABLE 2A Item 2

**Item 2 Scenario:**

Case 2: A 45-year-old male holds a position that is designated as safety-sensitive. Therefore, he was subjected to random employment drug testing. A urine sample was taken and submitted for analysis.

**Item Contents and Preparation Concentration:** Benzoyllecgonine (2000ng/mL)  
Ecgonine methyl ester (400ng/mL)

Webcode	Screening Results
2UUFXZ	cocaine
3C7PB7	cocaine and metabolites
424NC8	Cocaine Metabolite
4GZUQW	Cocaine
4X4DF8	BENZOYLECOGNINE[sic] Panel
69GZ4Y	COCAINE -M
77QDMV	Class: Cocaine Metabolites
7AUYKT	Cocaine
7T2DVT	Cocaine class
83JHFX	Cocaine metabolite 150
8K7XJU	Cocaine
AUM24Y	Cocaine metabolite
BCGGGU	COCAINA[sic] AND METABOLITES
BP7F9W	Cocaine
CGQUYT	BENZOILECGONINE[sic]
CKQ6VT	BENZOYLECGONINE
CMT7VP	Benzoyllecgonine
EQ8KCV	Cocaine Metabolite

TABLE 2A Item 2

Webcode	Screening Results
ETT6JK	COCAINE, BENZOYLECGONINE
F63YCP	Cocaine Metabolite
FGY66M	*Cocaine
FQK9CM	Methylecgonine
FX3H2J	Cocaine / Benzoyl ecgonine
GGUAYL	Cocaine Metabolite
H789GR	Benzoylecognine[sic] (cocaine metab)
H797RM	Cocaine Metabolites
JRLDFL	Cocaine Metabolite
K9TWRH	Cocaine
KJQX4L	cocaine metabolite
KTGAPF	benzoylecgonine, ecgonine methyl ester
LX2XDH	ecgonine methyl ester, benzoylecgonine
MD9C9K	Cocaine Metabolite
P4V2VB	Cocaine
PUAXNC	Benzoylecgonine (Cocaine assay)
QHWXRH	screened positive for cocaine metabolite
QH XV3E	Cocaine metabolite
QJTD4F	COCAINA[sic]
R92EQF	Cocaine
RAWXRG	Cocaine metabolite

TABLE 2A Item 2

Webcode	Screening Results
RREYMJ	Cocaine Metabolite
TUY6L7	Cocaine Metabolite
UKTVE8	Cocaine
WKHTVC	Cocaine Metabolite
WWJ726	Cocaine
X7V6Z6	Cocaine Metabolite
XHCPK2	Cocaine
Y3QWAZ	Cocaine
YMY86	Cocaine (Metabolite)
YUZB42	Cocaine/metabolite(s)

Response Summary for Item 2	Participants: 49
Cocaine:	42
Benzoyllecgonine and/or Ecgonine methyl ester:	10
<p>Totals may add up to more than the total number of participants because some participants reported multiple drugs/analytes.</p>	

## Confirmatory Results - Item 2

*What drugs/metabolites were detected in Item 2?*

TABLE 2B Item 2

**Item 2 Scenario:**

Case 2: A 45-year-old male holds a position that is designated as safety-sensitive. Therefore, he was subjected to random employment drug testing. A urine sample was taken and submitted for analysis.

**Item Contents and Preparation Concentration:**      Benzoyllecgonine (2000ng/mL)  
Ecgonine methyl ester (400ng/mL)

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
2UUFXZ	cocaine	✓			
3C7PB7	benzoyllecgonine	✓			
	ecgonine methyl ester	✓			
	cocaine	✓			
424NC8	benzoyllecgonine	✓			
	ecgonine methyl ester	✓			
4GZUQW	Benzoyllecgonine[sic]	✓			
	Ecgonine methyl ester	✓			
69GZ4Y	No drugs/metabolites detected.				
6ZQEYZ	BENZOILECGONINA[sic]	✓			
	ECGONINA METIL ESTER [sic]	✓			
77QDMV	Benzoyllecgonine	✓			
7AUYKT	Benzoyl Ecgonine		2056		µg/L
	Methyl Ecgonine		250		µg/L
7T2DVT	Benzoyllecgonine	✓			
7ZKJRZ	BENZOYLECGONINE	✓			
	ECGONINE METHYL ESTER	✓			
83JHFX	Cocaine	✓			

TABLE 2B Item 2

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
8K7XJU	Benzoyl ecgonine	✓			
	Methylecgonine	✓			
AUM24Y	Benzoyl ecgonine		1703	256	ng/mL
BCGGGU	BEZOILECGONINA[sic]	✓			
	ECGONINA METIL ESTER [sic]	✓			
BP7F9W	Benzoyl ecgonine	✓			
CGQUYT	BENZOILECGONINE[sic]	✓			
CKQ6VT	BENZOYLECGONINE	✓			
CMT7VP	Benzoyl ecgonine	✓			
EQ8KCV	Benzoyl ecgonine	✓			
	Methylecgonine	✓			
ETT6JK	BENZOYLECGONINE	✓			
	COCAINE	✓			
F63YCP	Benzoyl ecgonine		1909		ng/mL
FGY66M	Benzoyl ecgonine[sic]	✓			
	Cocaine	✓			
FQK9CM	Urine Sample	✓			
FX3H2J	Benzoyl ecgonine	✓			
GGUAYL	Benzoyl ecgonine				
	Ecgonine methyl ester	✓			
H789GR	Benzoyl ecgonine[sic]	✓			
H797RM	Benzoyl ecgonine	✓			
	Methylecgonine	✓			

TABLE 2B Item 2

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
JRLDFL	Benzoylecgonine	✓			
	Methylecgonine	✓			
K9TWRH	Benzoylecgonine[sic]	✓			
KJQX4L	benzoylecgonine		> 1000		ng/mL
	ecgonine methyl ester	✓			
KTGAPF	benzoyl ecgonine		1960	20%	ng/mL
	ecgonine methyl ester		290	20%	ng/mL
LX2XDH	ecgonine methyl ester	✓			
MD9C9K	Benzoylecgonine	✓			
	Methylecgonine	✓			
P4V2VB	No drugs/metabolites detected.				
PUAXNC	Benzoylecgonine	✓			
	Cocaine	✓			
QHWXRH	Ecgonine Methyl Ester	✓			
QH XV3E	benzoylecgonine	✓			
	ecgonine methyl ester	✓			
	cocaine	✓			
QJTD4F	BENZOYLECGONINE	✓			
R92EQF	Benzoylecgonine	✓			
	Ecgonine Methyl Ester	✓			
RAWXRG	Benzoylecgonine	✓			
RREYMJ	Benzoylecgonine	✓			
	Ecgonine Methyl Ester	✓			

TABLE 2B Item 2

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
TUY6L7	Benzoyllecgonine[sic]	✓	Positive		
WKHTVC	Ecgonine Methyl Ester	✓			
WVJ726	Benzoyllecgonine	✓			
X7V6Z6	Benzoyllecgonine		1.59		ug/mL
	Cocaine		0.05		ug/mL
Y3QWAZ	Benzoyllecgonine	✓			
	Ecgonine methyl ester	✓			
YMY86	Benzoyllecgonine		1.8		mcg/mL
YUZB42	Benzoyllecgonine	✓			
	Methylecgonine	✓			

Response Summary for Item 2		Participants: 48
Benzoyllecgonine:	40	
Ecgonine methyl ester:	23	
No drugs/metabolites detected:	2	
Other:	9	
Totals may add up to more than the total number of participants because some participants reported multiple drugs/metabolites.		

## Raw Data - Item 2

*List of raw data determinations in ng/mL.*

TABLE 2C Item 2

**Item 2 Raw Data - Benzoyllecgonine**  
**Preparation concentration: 2000ng/mL**

Webcode	Raw Data (ng/mL)		Participant Mean
7AUYKT	2,056.000		2,056.000
AUM24Y	1,703.000		1,703.000
F63YCP	1,906.330	1,912.340	1,909.335
KTGAPF	1,933.000	1,988.000	1,960.500
X7V6Z6	1,601.810	1,590.500	1,596.155
YMY86	1,830.000		1,830.000

### Statistical Analysis for Item 2- Benzoyllecgonine

Please note statistical analysis has not been provided due to the low number of raw data responses.



TABLE 2C Item 2  
Item 2 Raw Data - Ecgonine methyl ester  
Preparation concentration: 400ng/mL

Webcode	Raw Data (ng/mL)	Participant Mean
7AUYKT	250.000	250.000
KTGAPF	292.000    281.000	286.500

**Statistical Analysis for Item 2- Ecgonine methyl ester**

Please note statistical analysis has not been provided due to the low number of raw data responses.

TABLE 2C Item 2  
Item 2 Raw Data - Other

Webcode	Analyte	Raw Data (ng/mL)	
X7V6Z6	Cocaine	54.470	54.940

Statistical Analysis for Item 2- Other

Please note statistical analysis is not provided for other drug responses.

## Reporting Procedures - Item 2

*If quantitative analysis was performed, the reported concentrations are:*

TABLE 2D Item 2

Webcode	Quantitative Reporting Procedures
69GZ4Y	The mean of duplicate/several determinations.
7AUYKT	A single determination.
AUM24Y	A single determination.
F63YCP	The mean of duplicate/several determinations.
KJQX4L	A single determination.
KTGAPF	The mean of duplicate/several determinations.
QJTD4F	A single determination.
X7V6Z6	The mean of duplicate/several determinations.
YMY86	A single determination.

Response Summary for Item 2	Participants: 9
A single determination:	5 (55.6%)
The mean of duplicate/several determinations:	4 (44.4%)
Other:	0 (0.0%)

## Method of Analysis - Item 2

TABLE 2E Item 2

Webcode	Method	Screening	Confirmatory	Quantitation
2UUFXZ	Immunoassay	✓		
	GC/MS		✓	
3C7PB7	Immunoassay	✓		
	GC/MS		✓	
424NC8	Immunoassay	✓		
	GC/MS		✓	
4GZUQW	Immunoassay	✓		
	LC-TOF MS	✓	✓	
4X4DF8	Immunoassay	✓		
69GZ4Y	Immunoassay			
	GC/MS		✓	
6ZQEYZ	GC/MS	✓	✓	
77QDMV	Immunoassay	✓		
	GC/MS		✓	
7AUYKT	Immunoassay	✓		
	GC/MS		✓	✓
7T2DVT	Immunoassay	✓		
	GC/MS		✓	
7ZKJRZ	Immunoassay	✓		
	GC/MS		✓	
83JHFX	Immunoassay	✓		
	GC/MS		✓	
8K7XJU	Immunoassay	✓		
	GC/MS	✓	✓	
AUM24Y	Immunoassay	✓		
	GC/MS		✓	✓
BCGGGU	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
BP7F9W	Immunoassay	✓		
	GC/MS		✓	

TABLE 2E Item 2

Webcode	Method	Screening	Confirmatory	Quantitation
CGQUYT	Immunoassay	✓		
	GC/MS		✓	
CKQ6VT	Immunoassay	✓		
	GC/MS		✓	
CMT7VP	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
EQ8KCV	Immunoassay	✓		
	GC/MS		✓	
ETT6JK	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	
F63YCP	Immunoassay	✓		
	GC/MS		✓	✓
FGY66M	Immunoassay	✓		
	GC/MS		✓	
FQK9CM	Immunoassay	✓		
	GC/MS		✓	
FX3H2J	Immunoassay	✓		
	GC/MS		✓	
GGUAYL	Immunoassay	✓		
	GC/MS		✓	
H789GR	Immunoassay	✓		
	GC/MS		✓	
H797RM	Immunoassay	✓		
	GC/MS		✓	
JRLDFL	Immunoassay	✓		
	GC/MS		✓	
K9TWRH	Immunoassay	✓		
	GC/MS		✓	
	LC-Orbitrap		✓	
KJQX4L	Immunoassay	✓		
	GC/MS	✓	✓	✓

TABLE 2E Item 2

Webcode	Method	Screening	Confirmatory	Quantitation
KTGAPF	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS		✓	✓
	LC-QTOF	✓		
LX2XDH	GC/MS		✓	
	LC/MS/MS	✓		
	Rapid Chromatographic Immunoassay	✓		
MD9C9K	Immunoassay	✓		
	GC/MS		✓	
P4V2VB	Immunoassay	✓		
PUAXNC	Immunoassay	✓		
	GC/MS		✓	
QHWXRH	Immunoassay	✓		
	GC/MS		✓	
QHVV3E	Immunoassay	✓		
	GC/MS		✓	
QJTD4F	Immunoassay	✓		
	GC/MS		✓	
R92EQF	Immunoassay	✓		
	GC/MS		✓	
RAWXRG	Immunoassay	✓		
	GC/MS		✓	
RREYMJ	Immunoassay	✓		
	GC/MS		✓	
TUY6L7	Immunoassay	✓		
	GC/MS		✓	
UKTVE8	Immunoassay	✓		
WKHTVC	Immunoassay	✓		
	GC/MS		✓	
WVJ726	Immunoassay	✓		
	GC/MS		✓	
X7V6Z6	Immunoassay	✓		
	GC/MS		✓	✓

TABLE 2E Item 2

Webcode	Method	Screening	Confirmatory	Quantitation
XHCPK2	Immunoassay	✓		
Y3QWAZ	Immunoassay	✓		
	GC/MS		✓	
YMY86	Immunoassay	✓		
	GC/MS	✓	✓	✓
	GC-NPD	✓		
YUZB42	Immunoassay	✓		
	GC/MS	✓	✓	

Response Summary for Item 2			Participants: 51		
	Screening	Confirmatory	Quantitation		
<b>Immunoassay:</b>	48	0	0		
<b>GC/MS:</b>	7	45	6		
<b>LC/MS:</b>	0	0	0		
<b>LC/MS/MS:</b>	2	4	1		
<b>Other:</b>	4	2	0		

## Additional Comments for Item 2

TABLE 2F Item 2

Webcode	Item 2 - Comments
2UUFXZ	Possible benzoylecgonine[sic] detected
4GZUQW	Cocaine was identified at a level that was too low to confirm
4X4DF8	We utilized ELISA and an Enzymatic Assay (for EtOH) and use Immunalysis Kits. It is not our practice to report a specific analyte as a (+) or (-). Calibrator Levels: ELISA Panels (ng/ml): Amphetamine 50, Benzodiazepines 50, Benzoylecgonine 50, Flunitrazepam 25, Ketamine 10, Methamphetamine 50, Opiates 25, Oxycodone 10, D9-THC 25, Zolpidem 10. Enzymatic Assay (g/dl): Ethyl Alcohol 0.01.
77QDMV	Inconclusive cocaine ions. Internal Standards used: Phenyltoloxamine, Heptabarbital.
83JHFX	Benzoylecgonine was confirmed; as per SOP, metabolites are not reported if the parent drug is confirmed.
8K7XJU	Benzoylecgonine Confirmation used Nalorphine as Internal Standard
AUM24Y	Internal Standards: Cocaine-d3, Benzoylecgonine-d3. Limits of Detection for Cocaine, Benzoylecgonine = 50 ng/mL.
EQ8KCV	IS-Benzoylecgonine-d5. Cocaine Metabolite cutoff 500 ng/ml.
FGY66M	*Oxybenzone - Theobromine were found in Item 2 sample. *Codiene-d3 used as internal standard.
FQK9CM	The technique used for analyzing the sample is Liquid-Liquid extraction
FX3H2J	"Cocaine D3 and Benzoyl ecgonine D3" were used as internal standards. Limit of detection was 25ng/mL.
GGUAYL	Possible cocaine detected but not confirmed. Internal standards used: SKF-525A.
H789GR	Caffeine indicated by GC-MS (lab would not confirm w/ 2nd test since not controlled).
KTGAPF	ISD for both quantitations = D3 benzoyl ecgonine
LX2XDH	Alere iCassette (THC) test device was used to screen for THC, referred to in 2-4[Table 2E Item 2 - Method of Analysis] as rapid chromatographic immunoassay.
P4V2VB	Cutoff for cocaine is 150 ng/mL.
PUAXNC	Acid Internal Reference Material - Heptabarbital. Base Internal Reference Material - Phenyltoloxamine.
RREYMJ	SKF-525A was used as the internal standard. Caffeine was also confirmed in the urine sample but was not reported as it was present in all three samples.
UKTVE8	Item 2 was only screened, no confirmatory test was done.
WKHTVC	If parent drug or a metabolite is detected in our initial confirmatory extraction we do not encourage or require additional extractions to confirm other suspected or indicated metabolites of that drug. For example if cocaine or ecgonine methyl ester was confirmed in the general basic drug confirmation we would not perform an additional extraction looking for benzoylecgonine.
X7V6Z6	Internal Standards- Cocaine D3, BZE D3. Limit of detection 50ng/mL.
XHCPK2	Analysed using randox evidence.
YUZH42	Immunoassay for Screening. GC/MS for Confirmation.



## Screening Results - Item 3

TABLE 3A Item 3

**Item 3 Scenario:**

Case 3: A 53-year-old female has agreed to submit to regular monitoring of her pain management for moderate chronic pain due to lung cancer. A urine sample has been submitted for analysis.

**Item Contents and Preparation Concentration:** Fentanyl (75ng/mL)  
Norfentanyl (260ng/mL)

Webcode	Screening Results
2UUFXZ	No drugs/metabolites detected. No drugs detected in the immunoassay screen. GC/MS used as the preliminary test for Fentanyl.
3C7PB7	Fentanyl and norfentanyl
424NC8	No drugs/metabolites detected.
4GZUQW	Fentanyl
4X4DF8	No drugs/metabolites detected.
69GZ4Y	No drugs/metabolites detected.
77QDMV	Narcotic: Fentanyl, norfentanyl
7AUYKT	No drugs/metabolites detected.
7T2DVT	No drugs/metabolites detected.
83JHFX	No drugs/metabolites detected.
8K7XJU	Fentanyl , Norfentanyl
AUM24Y	No drugs/metabolites detected.
BCGGGU	No drugs/metabolites detected.
BP7F9W	No drugs/metabolites detected.
CKQ6VT	No drugs/metabolites detected.
CMT7VP	Fentanyl
EQ8KCV	No drugs/metabolites detected.
ETT6JK	No drugs/metabolites detected.
F63YCP	Fentanyl
FGY66M	No drugs/metabolites detected.

TABLE 3A Item 3

Webcode	Screening Results
FQK9CM	No drugs/metabolites detected.
FX3H2J	Fentanyl
G84PTN	No drugs/metabolites detected. CANNABINOID, COCAINE, BENZODIACEPINES, ANPHETAMINES, BARBITURATES AND OPIATES. [sic]
GGUAYL	No drugs/metabolites detected.
H789GR	fentanyl/fentanyl analogs
H797RM	Fentanyl, Norfentanyl
K9TWRH	No drugs/metabolites detected.
KJQX4L	fentanyl, norfentanyl
KTGAPF	fentanyl, norfentanyl
LX2XDH	norfentanyl, fentanyl
MD9C9K	No drugs/metabolites detected.
P4V2VB	No drugs/metabolites detected.
PUAXNC	Fentanyl
QHWXRH	No drugs/metabolites detected.
QH XV3E	No drugs/metabolites detected.
QJTD4F	No drugs/metabolites detected.
R92EQF	Fentanyl
RAWXRG	Fentanyl
RREYMJ	No drugs/metabolites detected.
TUY6L7	Fentanyl
UKTVE8	No drugs/metabolites detected.
WKHTVC	No drugs/metabolites detected.
WVJ726	Amphetamine -'detected' only

TABLE 3A Item 3

Webcode	Screening Results
X7V6Z6	No drugs/metabolites detected.
XHCPK2	No drugs/metabolites detected.
Y3QWAZ	Fentanyl
YMYY86	No drugs/metabolites detected.
YUZH42	Fentanyl, Norfentanyl

Response Summary for Item 3	Participants: 48
Fentanyl and/or Norfentanyl:	18
Opiates and/or Narcotics:	2
Other:	2
No drugs/metabolites detected:	29
<p>Totals may add up to more than the total number of participants because some participants reported multiple drugs/analytes.</p>	

## Confirmatory Results - Item 3

*What drugs/metabolites were detected in Item 3?*

TABLE 3B Item 3

**Item 3 Scenario:**

Case 3: A 53-year-old female has agreed to submit to regular monitoring of her pain management for moderate chronic pain due to lung cancer. A urine sample has been submitted for analysis.

**Item Contents and Preparation Concentration:** Fentanyl (75ng/mL)  
Norfentanyl (260ng/mL)

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
2UUFXZ	fentanyl	✓			
3C7PB7	Fentanyl	✓			
424NC8	fentanyl	✓			
	norfentanyl	✓			
4GZUQW	Fentanyl	✓			
6ZQEYZ	FENTANYL	✓			
77QDMV	Fentanyl	✓			
	Norfentanyl	✓			
7AUYKT	Fentanyl	✓			
	Norfentanyl	✓			
7T2DVT	Fentanyl	✓			
7ZKJRZ	FENTANYL	✓			
83JHFX	Fentanyl	✓			
8K7XJU	Fentanyl	✓			
	Norfentanyl	✓			
BCGGGU	FENTANYL				
CGQUYT	FENTANYL	✓			
CKQ6VT	No drugs/metabolites detected.				
CMT7VP	Fentanyl	✓			
EQ8KCV	Fentanyl	✓			

TABLE 3B Item 3

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
ETT6JK	No drugs/metabolites detected.				
F63YCP	Fentanyl	✓			
FGY66M	Mescaline	✓			
FQK9CM	No drugs/metabolites detected.				
FX3H2J	Fentanyl		65.95	±13.2	ng/mL
	Norfentanyl		244.40	±48.9	ng/mL
G84PTN	FENTANYL	✓			
GGUAYL	Fentanyl	✓			
	Norfentanyl	✓			
H789GR	Fentanyl	✓			
H797RM	Fentanyl	✓			
	Norfentanyl	✓			
JRLDFL	Fentanyl	✓			
	Norfentanyl	✓			
K9TWRH	Fentanyl	✓			
KJQX4L	fentanyl	✓			
	norfentanyl	✓			
KTGAPF	fentanyl		73	15%	ng/mL
	norfentanyl	✓			
LX2XDH	fentanyl	✓			
	norfentanyl	✓			
MD9C9K	Fentanyl	✓			
	Norfentanyl	✓			
P4V2VB	No drugs/metabolites detected.				
PUAXNC	Fentanyl	✓			
QHWXRH	No drugs/metabolites detected.				

TABLE 3B Item 3

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
QH XV3E	fentanyl	✓			
QJTD4F	No drugs/metabolites detected.				
R92EQF	Fentanyl	✓			
RAWXRG	Fentanyl	✓			
RREYMJ	Fentanyl	✓			
	Norfentanyl	✓			
TUY6L7	Fentanyl	✓	Positive		
WKHTVC	No drugs/metabolites detected.				
WVJ726	Fentanyl	✓			
Y3QWAZ	Fentanyl	✓			
YMY86	No drugs/metabolites detected.				
YUZB42	Fentanyl	✓			
	Norfentanyl	✓			

Response Summary for Item 3		Participants: 45
Fentanyl:	36	
Norfentanyl:	14	
No drugs/metabolites detected:	8	
Other:	1	
Totals may add up to more than the total number of participants because some participants reported multiple drugs/metabolites.		

## **Raw Data - Item 3**

*List of raw data determinations in ng/mL.*

TABLE 3C Item 3

**Item 3 Raw Data - Fentanyl**  
**Preparation concentration: 75ng/mL**

<b>Webcode</b>	<b>Raw Data (ng/mL)</b>			<b>Participant Mean</b>
FX3H2J	64.770	64.920	65.180	64.957
KTGAPF	72.600	72.500		72.550

### **Statistical Analysis for Item 3 - Fentanyl**

Please note statistical analysis has not been provided due to the low number of raw data responses.

TABLE 3C Item 3  
**Item 3 Raw Data - Norfentanyl**  
**Preparation concentration: 260ng/mL**

<b>Webcode</b>	<b>Raw Data (ng/mL)</b>			<b>Participant Mean</b>
FX3H2J	244.280	245.370	243.650	244.433

**Statistical Analysis for Item 3 - Norfentanyl**

Please note statistical analysis has not been provided due to the low number of raw data responses.



## Reporting Procedures - Item 3

*If quantitative analysis was performed, the reported concentrations are:*

TABLE 3D Item 3

WebCode	Quantitative Reporting Procedures
69GZ4Y	A single determination.
FX3H2J	The mean of duplicate/several determinations.
KTGAPF	The mean of duplicate/several determinations.
QJTD4F	A single determination.

Response Summary for Item 3	Participants: 4
A single determination:	2 (50.0%)
The mean of duplicate/several determinations:	2 (50.0%)
Other:	0 (0.0%)

## Method of Analysis - Item 3

TABLE 3E Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
2UUFXZ	Immunoassay	✓		
	GC/MS	✓	✓	
3C7PB7	Immunoassay	✓		
	GC/MS	✓	✓	
424NC8	GC/MS	✓	✓	
4GZUQW	Immunoassay	✓		
	LC-TOF MS	✓	✓	
4X4DF8	Immunoassay	✓		
69GZ4Y	Immunoassay	✓		
6ZQEYZ	GC/MS	✓	✓	
77QDMV	Immunoassay	✓		
	GC/MS		✓	
	2nd GC/MS for screening	✓		
7AUYKT	Immunoassay	✓		
	GC/MS		✓	
7T2DVT	Immunoassay	✓		
	GC/MS	✓	✓	
7ZKJRZ	Immunoassay	✓		
	GC/MS		✓	
83JHFX	Immunoassay	✓		
	GC/MS		✓	
8K7XJU	Immunoassay	✓		
	GC/MS	✓	✓	
AUM24Y	Immunoassay	✓		
BCGGGU	GC/MS		✓	
	LC/MS/MS		✓	
BP7F9W	Immunoassay	✓		

TABLE 3E Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
CGQUYT	GC/MS		✓	
CMT7VP	LC/MS/MS	✓	✓	
EQ8KCV	Immunoassay	✓		
	GC/MS	✓	✓	
ETT6JK	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS	✓	✓	
F63YCP	GC/MS		✓	
FGY66M	Immunoassay	✓		
	GC/MS		✓	
FQK9CM	Immunoassay	✓		
	GC/MS		✓	
FX3H2J	Immunoassay	✓		
	GC/MS		✓	✓
G84PTN	Immunoassay	✓		
	GC/MS		✓	
GGUAYL	Immunoassay	✓		
	GC/MS		✓	
H789GR	Immunoassay	✓		
	GC/MS		✓	
H797RM	Immunoassay	✓		
	GC/MS	✓	✓	
JRLDFL	Immunoassay	✓		
	GC/MS	✓	✓	
K9TWRH	Immunoassay	✓		
	GC/MS		✓	
	LC-Orbitrap		✓	
KJQX4L	Immunoassay	✓		
	GC/MS	✓	✓	

TABLE 3E Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
KTGAPF	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS			✓
	LC-QTOF	✓	✓	
LX2XDH	GC/MS		✓	
	LC/MS/MS	✓		
	Rapid Chromatographic Immunoassay	✓		
MD9C9K	Immunoassay	✓		
	GC/MS		✓	
P4V2VB	Immunoassay	✓		
PUAXNC	Immunoassay	✓		
	GC/MS	✓	✓	
QHWXRH	Immunoassay	✓		
	GC/MS			
QH XV3E	GC/MS		✓	
QJTD4F	Immunoassay	✓		
R92EQF	Immunoassay	✓		
	GC/MS	✓	✓	
RAWXRG	Immunoassay	✓		
	GC/MS	✓	✓	
RREYMJ	Immunoassay	✓		
	GC/MS		✓	
TUY6L7	Immunoassay	✓		
	GC/MS	✓	✓	
UKTVE8	Immunoassay	✓		
WKHTVC	Immunoassay	✓		
	GC/MS		✓	
WVJ726	Immunoassay	✓		
	GC/MS	✓	✓	

TABLE 3E Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
X7V6Z6	Immunoassay	✓		
XHCPK2	Immunoassay	✓		
Y3QWAZ	Immunoassay	✓		
	GC/MS		✓	
YMY86	GC-NPD	✓		
	Immunoassay	✓		
	GC/MS	✓		
YUZH42	GC/MS	✓	✓	

Response Summary for Item 3		Participants: 51		
		Screening	Confirmatory	Quantitation
<b>Immunoassay:</b>		42	0	0
<b>GC/MS:</b>		19	37	1
<b>LC/MS:</b>		0	0	0
<b>LC/MS/MS:</b>		3	3	1
<b>Other:</b>		5	3	0

## Additional Comments for Item 3

TABLE 3F Item 3

WebCode	Item 3 - Comments
2UJFXZ	Possible norfentanyl detected
4X4DF8	We utilized ELISA and an Enzymatic Assay (for EtOH) and use Immunalysis Kits. It is not our practice to report a specific analyte as a (+) or (-). Calibrator Levels: ELISA Panels (ng/ml): Amphetamine 50, Benzodiazepines 50, Benzoylcegonine 50, Flunitrazepam 25, Ketamine 10, Methamphetamine 50, Opiates 25, Oxycodone 10, D9-THC 25, Zolpidem 10. Enzymatic Assay (g/dl): Ethyl Alcohol 0.01.
77QDMV	Internal Standards used: Phenyltoloxamine, Heptabarbital.
83JHFX	Norfentanyl was confirmed; as per SOP, metabolites are not reported if the parent drug is confirmed.
BP7F9W	Confirmation not performed as screening results were negative
EQ8KCV	IS-Phenyltoloxamine
FGY66M	*(Theobromine - oxybenzone) were found in Item 3 sample. *Codiene-d3 used as internal standard.
FQK9CM	The technique used for analyzing the sample is liquid-liquid extraction
FX3H2J	"Fentanyl D3 & Norfentanyl D3" were used as internal standards. Limit of detection was 10ng/mL.
G84PTN	SCREENING BY INMUNOASSAY: CUTT-OF CANNABINOIDS:50ng/ml, COCAINE:300ng/ml, BENZODIACEPINAS :200ng/ml, BARBITURATES: 200 ng/ml, OPIATES: 300 ng/ml, AMPHETAMINES:1000 ng/ml. [sic]
GGUAYL	Internal standards used: SKF-525A
H789GR	Caffeine indicated by GC-MS (lab would not confirm by 2nd test since not controlled).
H797RM	Promazine used as internal standard in both screening and confirmatory drug screens performed using GC/MS.
KTGAPF	ISD for quantitation = D5-fentanyl
LX2XDH	Alere iCassette (THC) test device was used to screen for THC, referred to in 3-4[Table 3E Item 3 - Method of Analysis] as rapid chromatographic immunoassay.
PUAXNC	Acid Internal Reference Material - Heptabarbital. Base Internal Reference Material - Phenyltoloxamine. Laboratory protocol does not require confirming metabolites if parent drug is detected and confirmed.
QJTD4F	NOT A NEGATIVE RESULT IS CONFIRMED
R92EQF	I initially screened this urine sample by immunoassay but all tests were negative. I was not sure if I should add the immunoassay method or not. I ended up using the GC/MS as my screening and confirmatory tests in order to confirm fentanyl.
RREYMJ	SKF-525A was used as the internal standard. Caffeine was also confirmed in the urine sample but was not reported as it was present in all three samples.
X7V6Z6	Screening assays used are: amphetamine, benzodiazepine, cocaine metabolite, ecstasy, ethyl alcohol, methadone, opiate, cannabinoid

## TABLE 3F Item 3

<b>WebCode</b>	<b>Item 3 - Comments</b>
XHCPK2	Analysed using randox evidence.
YUZB42	GC/MS used for screening. GC/MS used for confirmation.

## Additional Test Comments

TABLE 4

WebCode	Additional Comments
KJQX4L	Our laboratory reports quantitative values in urine only for drugs with a legal statute (“per se” value). All other drugs are reported qualitatively in urine.
PUAXNC	Laboratory protocol does not require confirming metabolites of a drug if the parent drug is detected and confirmed.



## Appendix: Data Sheet

Collaborative Testing Services ~ Forensic Testing Program

### **Test No. 15-5671: Urine Drug Analysis**

DATA MUST BE RECEIVED BY November 30, 2015 TO BE INCLUDED IN THE REPORT

Participant Code:

WebCode:

#### **Accreditation Release Statement**

CTS submits external proficiency test data directly to ASCLD/LAB and ANAB. Please select one of the following statements to ensure your data is handled appropriately.

This participant's data is intended for submission to ASCLD/LAB and/or ANAB. (Accreditation Release section on the last page must be completed and submitted.)

This participant's data is NOT intended for submission to ASCLD/LAB or ANAB.

#### **Scenario:**

Investigators have submitted three urine specimens from three separate cases for your analysis. Using your laboratory's procedures, analyze each sample and report the presence of any drugs and/or metabolites.

Case 1: A 25-year-old female was arrested for possession of Diazepam without a prescription last year and is subject to drug testing as part of her parole. After her parole officer observed her exhibiting poor balance, slurred speech, and trouble concentrating, he ordered that she submit to a drug test. Her urine sample has been submitted for analysis.

Case 2: A 45-year-old male holds a position that is designated as safety-sensitive. Therefore, he was subjected to random employment drug testing. A urine sample was taken and submitted for analysis.

Case 3: A 53-year-old female has agreed to submit to regular monitoring of her pain management for moderate chronic pain due to lung cancer. A urine sample has been submitted for analysis.

#### **Instructions:**

- Please do not report the presence/concentration of drugs in concentrations less than 10ng/mL.
- The purpose of this test is the examination of drugs other than alcohol; please test accordingly. Samples may contain methanol and acetonitrile as artifacts from production.

#### **Items Submitted (Sample Pack UDRG):**

- Item 1: Urine sample from Case 1
- Item 2: Urine sample from Case 2
- Item 3: Urine sample from Case 3

**Please return all pages of this data sheet.**

Page 1 of 9

Participant Code:

WebCode:

**Screening Results for Item 1:**

**1-1.) Please indicate the screening results for Item 1**

- No drugs detected utilizing screening methods.
- Drug(s) detected (list each class and/or drug name below).

**Confirmatory Results for Item 1:**

**1-2.) What drugs/metabolites were detected in Item 1? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.**

The number of boxes shown does not indicate the number of analytes present. If additional space is needed, copy this page or attach your own form following this layout.

- No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
_____	<input type="checkbox"/>	_____	_____	( _____ )
Date(s) Quantitative Analysis Performed on Analyte: _____				
<b>Raw Data (ng/mL):</b>				
_____	_____	_____	_____	_____

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
_____	<input type="checkbox"/>	_____	_____	( _____ )
Date(s) Quantitative Analysis Performed on Analyte: _____				
<b>Raw Data (ng/mL):</b>				
_____	_____	_____	_____	_____

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
_____	<input type="checkbox"/>	_____	_____	( _____ )
Date(s) Quantitative Analysis Performed on Analyte: _____				
<b>Raw Data (ng/mL):</b>				
_____	_____	_____	_____	_____

**Please return all pages of this data sheet.**

Participant Code:

WebCode:

**Results for Item 1 (continued):**

**1-3.) If quantitative analysis was performed, are the reported concentrations for Item 1:**

- A single determination?       The mean of duplicate / several determinations?
- Other? (Specify): \_\_\_\_\_

**1-4.) Please check the methods used to analyze Item 1 by selecting whether each method used was for screening, confirmatory testing and/or quantitation.**

<u>Method Used</u>	<u>Screening</u>	<u>Confirmatory</u>	<u>Quantitation</u>
Immunoassay	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
GC/MS	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
LC/MS	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
LC/MS/MS	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other: _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other: _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**1-5.) Date Samples Received:** \_\_\_\_\_

**1-6.) Additional Comments for Item 1**

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

---



---



---



---



---



---



---



---

Participant Code:

WebCode:

**Screening Results for Item 2:**

**2-1.) Please indicate the screening results for Item 2**

- No drugs detected utilizing screening methods.
- Drug(s) detected (list each class and/or drug name below).

---



---

**Confirmatory Results for Item 2:**

**2-2.) What drugs/metabolites were detected in Item 2? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.**

The number of boxes shown does not indicate the number of analytes present. If additional space is needed, copy this page or attach your own form following this layout.

- No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
_____	<input type="checkbox"/>	_____	_____	( _____ )
Date(s) Quantitative Analysis Performed on Analyte: _____				
<b>Raw Data (ng/mL):</b>				
_____	_____	_____	_____	_____

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
_____	<input type="checkbox"/>	_____	_____	( _____ )
Date(s) Quantitative Analysis Performed on Analyte: _____				
<b>Raw Data (ng/mL):</b>				
_____	_____	_____	_____	_____

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
_____	<input type="checkbox"/>	_____	_____	( _____ )
Date(s) Quantitative Analysis Performed on Analyte: _____				
<b>Raw Data (ng/mL):</b>				
_____	_____	_____	_____	_____

**Please return all pages of this data sheet.**

Participant Code:

WebCode:

**Results for Item 2 (continued):**

**2-3.) If quantitative analysis was performed, are the reported concentrations for Item 2:**

- A single determination?       The mean of duplicate / several determinations?
- Other? (Specify): \_\_\_\_\_

**2-4.) Please check the methods used to analyze Item 2 by selecting whether each method used was for screening, confirmatory testing and/or quantitation.**

<u>Method Used</u>	<u>Screening</u>	<u>Confirmatory</u>	<u>Quantitation</u>
Immunoassay	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
GC/MS	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
LC/MS	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
LC/MS/MS	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other: _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other: _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**2-5.) Date Samples Received:** \_\_\_\_\_

**2-6.) Additional Comments for Item 2**

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

---



---



---



---



---



---



---



---

Participant Code:

WebCode:

**Screening Results for Item 3:**

**3-1.) Please indicate the screening results for Item 3**

- No drugs detected utilizing screening methods.
- Drug(s) detected (list each class and/or drug name below).

---



---

**Confirmatory Results for Item 3:**

**3-2.) What drugs/metabolites were detected in Item 3? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.**

The number of boxes shown does not indicate the number of analytes present. If additional space is needed, copy this page or attach your own form following this layout.

- No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
_____	<input type="checkbox"/>	_____	_____	( _____ )
Date(s) Quantitative Analysis Performed on Analyte: _____				
<b>Raw Data (ng/mL):</b>				
_____	_____	_____	_____	_____

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
_____	<input type="checkbox"/>	_____	_____	( _____ )
Date(s) Quantitative Analysis Performed on Analyte: _____				
<b>Raw Data (ng/mL):</b>				
_____	_____	_____	_____	_____

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
_____	<input type="checkbox"/>	_____	_____	( _____ )
Date(s) Quantitative Analysis Performed on Analyte: _____				
<b>Raw Data (ng/mL):</b>				
_____	_____	_____	_____	_____

**Please return all pages of this data sheet.**

Participant Code:

WebCode:

**Results for Item 3 (continued):**

**3-3.) If quantitative analysis was performed, are the reported concentrations for Item 3:**

- A single determination?       The mean of duplicate / several determinations?
- Other? (Specify): \_\_\_\_\_

**3-4.) Please check the methods used to analyze Item 3 by selecting whether each method used was for screening, confirmatory testing and/or quantitation.**

<u>Method Used</u>	<u>Screening</u>	<u>Confirmatory</u>	<u>Quantitation</u>
Immunoassay	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
GC/MS	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
LC/MS	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
LC/MS/MS	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other: _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other: _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**3-5.) Date Samples Received:** \_\_\_\_\_

**3-6.) Additional Comments for Item 3**

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

---



---



---



---



---



---



---



---

Participant Code:

WebCode:

**Additional Comments on Test**

---

---

---

---

---

---

---

---

**Return Instructions:** Data must be received via online data entry, fax (please include a cover sheet), or mail by *November 30, 2015* to be included in the report. Emailed data sheets are not accepted.

**QUESTIONS?**

TEL: +1-571-434-1925 (8 am - 4:30 pm EST)  
EMAIL: [forensics@cts-interlab.com](mailto:forensics@cts-interlab.com)  
[www.ctsforensics.com](http://www.ctsforensics.com)

Participant Code:

ONLINE DATA ENTRY: [www.cts-portal.com](http://www.cts-portal.com)

FAX: +1-571-434-1937

MAIL: Collaborative Testing Services, Inc.  
P.O. Box 650820  
Sterling, VA 20165-0820 USA

**Please return all pages of this data sheet.**



## Collaborative Testing Services ~ Forensic Testing Program

**RELEASE OF DATA TO ACCREDITATION BODIES**

The following Accreditation Releases will apply only to:

Participant Code:

WebCode:

for Test No. **15-5671: Urine Drug Analysis**

This release page must be completed and received by **November 30, 2015** to have this participant's submitted data included in the reports forwarded to the respective Accreditation Bodies.

**ASCLD/LAB RELEASE**

If your lab has been accredited by ASCLD/LAB and you are submitting this data as part of their external proficiency test requirements, have the laboratory's designated individual complete the following.

**The information below must be completed in its entirety for the results to be submitted to ASCLD/LAB.**

ASCLD/LAB Legacy Certificate No. \_\_\_\_\_ ASCLD/LAB International Certificate No. \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

Laboratory Name \_\_\_\_\_

Location (City/State) \_\_\_\_\_

**ANAB RELEASE**

If your laboratory maintains its accreditation through ANAB, please complete the following form in its entirety to have your results forwarded.

ANAB Certificate No. \_\_\_\_\_

Signature and Title \_\_\_\_\_ Date \_\_\_\_\_

Laboratory Name \_\_\_\_\_

Location (City/State) \_\_\_\_\_

**Accreditation Release****Return Instructions**

*Please submit the completed Accreditation Release at the same time as your full data sheet. See Data Sheet Return Instructions on the previous page.*

*Questions? Contact us 8 am-4:30 pm EST  
Telephone: +1-571-434-1925  
email: forensics@cts-interlab.com*

**Please return all pages of this data sheet.**

Page 9 of 9